Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Data on Covalent BTK Inhibitors for the Treatment of R/R Mantle Cell Lymphoma

July 28th 2023

Drs Kami Maddocks and Alexey Danilov review data from ongoing studies evaluating covalent BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Dr Danilov on Treatment Considerations in High-Risk MCL

July 24th 2023

Alexey Danilov, MD, PhD, discusses considerations for varying treatment approaches in patients with high-risk mantle cell lymphoma.

Dr Burke on Ongoing Investigations of Targeted Therapy Regimens in MCL

July 20th 2023

John M. Burke, MD, discusses several ongoing or upcoming investigations of targeted therapy in mantle cell lymphoma.

Real-World Analysis Shows Brexu-Cel Elicits Higher CR Rate in Patients With R/R MCL Given Fewer Lines of Prior Therapy

July 20th 2023

Nausheen Ahmed, MD, explains the rationale for examining real-world outcomes observed with the use of brexu-cel in the treatment of patients with relapsed/refractory mantle cell lymphoma, details the key efficacy and safety findings from the overall population and different subgroups, and discusses what will be gained with longer follow-up of the study.

Bruton Kinase Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma

July 20th 2023

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, discuss the evolution of BTK inhibitors and how they have changed treatment approaches in clinical practice.

Role of Maintenance Therapy in Newly Diagnosed Mantle Cell Lymphoma

July 20th 2023

Experts explain the role of maintenance therapy in mantle cell lymphoma and how it impacts the risk of disease progression.

Dr Ahmed on the Rationale for Investigating Real-World Outcomes of Brexu-Cel in R/R MCL

July 19th 2023

Nausheen Ahmed, MD, discusses the rationale for investigating real-world outcomes of patients with relapsed/refractory mantle cell lymphoma treated with brexucabtagene autoleucel.

Phase 1b Data Support Continued Investigation of Acalabrutinib Plus BR in MCL

July 19th 2023

Tycel Phillips, MD, discusses the rationale and design of a phase 1b trial investigating acalabrutinib plus bendamustine and rituximab in patients with mantle cell lymphoma, highlights key efficacy and safety findings in the treatment-naïve and relapsed/refractory patient cohorts, and postulated next steps on the horizon for investigating BTK inhibitors in combination with chemotherapy in this patient population.

Dr Danilov on Questions Remaining Across the Treatment Landscape of MCL

July 17th 2023

Alexey Danilov, MD, PhD, discusses lingering questions that remain across the treatment landscape of mantle cell lymphoma.

Dr O’Brien on the Potential Role for Noncovalent BTK Inhibitors in MCL and CLL

July 13th 2023

Susan M. O’Brien, MD, discusses the potential role for noncovalent BTK inhibitors in the treatment of patients with mantle cell lymphoma or chronic lymphocytic leukemia.

Dr O’Brien on the Use of Pirtobrutinib in BTK Inhibitor-Resistant MCL and CLL

June 30th 2023

Susan M. O’Brien, MD, discusses the use of pirtobrutinib for patients with hematologic malignancies who developed resistance to BTK inhibition.

Examining the Role of BTK Inhibitors in Mantle Cell Lymphoma

June 27th 2023

As part of the diagnostic work-up for a patient with newly diagnosed MCL, it is important to establish prognostic disease biology factors such as classical nodal morphology vs blastoid variant vs leukemic variant, TP53 mutation status, and Ki-67 reflective of proliferation.

Dr Ahmed on Real-World Findings With Brexu-Cel in MCL

June 21st 2023

Nausheen Ahmed, MD, discusses findings from a real-world subgroup analysis of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma.

Dr Phillips on the Preliminary Efficacy of Acalabrutinib Plus BR in MCL

June 20th 2023

Tycel Phillips, MD, MPH, discusses the updated safety profile and clinical activity seen with the addition of acalabrutinib to bendamustine and rituximab in patients with mantle cell lymphoma.

Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma

June 19th 2023

The CAR T-cell therapy lisocabtagene maraleucel produced rapid and durable responses in heavily pretreated patients with relapsed/refractory mantle cell lymphoma.

Ibrutinib, Obinutuzumab, Venetoclax Triplet Elicits Sustained Clinical Benefit in Mantle Cell Lymphoma

June 19th 2023

The combination of ibrutinib, obinutuzumab, and venetoclax was associated with prolonged survival in patients with newly diagnosed or relapsed/refractory mantle cell lymphoma.

Dr Shah on Long-Term Survival Data For Pirtobrutinib in BTK Inhibitor–Pretreated R/R MCL

June 16th 2023

Nirav N. Shah, MD, discusses the long-term efficacy of pirtobrutinib in patients with heavily pretreated, relapsed/refractory mantle cell lymphoma with previous exposure to covalent BTK inhibitors, according to updated data from the phase 1/2 BRUIN trial.

Dr Burke on the Influence of the SHINE and TRIANGLE Trials on Ibrutinib Use in MCL

June 15th 2023

John M. Burke, MD, discusses the influence of two key BTK inhibitor combination studies on therapeutic approaches for patients with previously untreated mantle cell lymphoma.

Real-World Analysis Supports Use of Brexu-Cel in Relapsed/Refractory MCL

June 15th 2023

The real-world efficacy and safety of brexucabtagene autoleucel were similar to the outcomes seen in the phase 2 ZUMA-2 trial, regardless of patients’ treatment history, according to results from a real-world subgroup analysis of patients with relapsed/refractory mantle cell lymphoma.

Dr Kambhampati on the Real-world Efficacy of Brexu-Cel in Heavily Pretreated Patients With MCL

June 13th 2023

Swetha Kambhampati, MD, discusses key findings from an analysis of real-world efficacy outcomes with brexucabtagene autoleucel in heavily pretreated patients with relapsed/refractory mantle cell lymphoma.